NDAORALTABLET
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BUCLADIN-S (buclizine hydrochloride) is an oral tablet approved in 1957 for the treatment of nausea and vomiting. The drug is a first-generation antihistamine with antiemetic properties used primarily for motion sickness and vertigo-related symptoms. It represents a legacy small-molecule product in a mature therapeutic category.
LOE Approaching
Product is in late-stage lifecycle with minimal commercial expansion; team focus likely on maintenance and regulatory compliance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BUCLADIN-S offers limited career growth due to LOE-approaching status and minimal linked job opportunities (0 current openings). This role suits professionals seeking stability in legacy product management or those transitioning to portfolio rationalization and lifecycle management expertise.
Brand ManagerField Sales Representative
Worked on BUCLADIN-S at Stuart Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.